In addition to tumorigenesis, another safety issue arose in a trial for ornithine transcarbamylase (OTC) deficiency, where a patient died from a severe immune reaction to a recombinant adenoviral vector delivering the OTC gene [15–17]. Here, OTC is linked to ornithine carbamoyltransferase deficiency.